Aurora Cannabis

Aurora Cannabis carries a Neutral rating with two-of-five conviction, reflecting a composite score in the mid-40s. Regulatory is the strongest pillar at roughly 69, supported by an 80 jurisdiction posture and an equally strong enforcement subscore following zero enforcement hits. Fundamentals contribute a moderate 57, led by a 71 gross-margin subscore, while weaker cash-runway and market-cap tiers constrain the benefit. Editorial registers 30 because CIN newsroom coverage produced no recent newsroom or brief hits. Market is the decisive drag at 15, entirely reflecting the minimum liquidity contribution and reported trading volume of zero in institutional pricing feeds.

Licensed fundamentals data show year-over-year revenue growth of approximately 5%, indicating expansion but not enough acceleration to offset weak profitability. Gross margin stands near 43%, providing the principal operating support within the fundamentals pillar. That support is outweighed by an operating margin near negative 26%, negative EBITDA of roughly 33 million, and a net loss approaching 136 million. A cash-burn ratio near 20% and a cash-runway subscore below 50 reinforce the stated stretched financial condition; profitability and capital durability remain unresolved. Primary regulatory filings provide the stronger evidence set: three filing events appeared during the latest 90-day period and eight during the latest 180-day period, with the most recent filing dated July 9, 2026. The resulting cadence subscore in the low-50s trails the stronger jurisdiction and enforcement components.

The clearest forward catalyst rests in the regulatory pillar, where Canada’s favorable jurisdiction posture and the absence of enforcement hits establish Aurora’s highest-quality support. More frequent, timely primary regulatory filings would lift the weaker cadence component and reinforce the company’s strongest pillar, while sustained gross-margin performance could preserve the fundamentals contribution despite continuing operating losses. Market and editorial scores offer little near-term confirmation, leaving regulatory execution as the most credible route to improved conviction. The single most important signal is the next primary regulatory filing arriving on a timely cadence without an accompanying enforcement hit.